Dengue Vaccine Market 2024 – Top Manufactures, Growth Rate, Revenue And Forecast To 2033

The dengue vaccine global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Dengue Vaccine Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –

The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.57 billion in 2023 to $0.64 billion in 2024 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to growing travel and urbanization, increasing demand for effective vaccines, increasing prevalence of foreign travel exposure, increasing healthcare services, and rising mass vaccinations.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to the increasing incidence of dengue, increasing initiatives by several organizations, increasing clinical trials, and growing emphasis on multi-strain and tetravalent vaccine formulations. Major trends in the forecast period include increasing demand for preventative vaccines, advancements in vaccine technology, development of combination vaccines, rise in research and clinical trials for new vaccine candidates, and focus on improving vaccine efficacy and safety profiles.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

Scope Of Dengue Vaccine Market

The Business Research Company’s reports encompass a wide range of information, including:

Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
Drivers: Examination of the key factors propelling market growth.
Trends: Identification of emerging trends and patterns shaping the market landscape.
Key Segments: Breakdown of the market into its primary segments and their respective performance.
Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
Macro Economic Factors: Assessment of broader economic elements impacting the market.

Dengue Vaccine Market Overview

Market Drivers –

The rising number of dengue fever cases is expected to propel the growth of the dengue vaccine markets going forward. Dengue fever is a viral infection spread by Aedes aegypti mosquitoes, causing high fever, headaches, joint pain, and rashes. The rise in dengue fever cases is due to climate change, urbanization, inadequate mosquito control, and viral evolution. The dengue vaccine works by activating the immune system to identify and combat the dengue virus. It lessens infection severity and reduces the risk of severe complications, helping to decrease cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the rising number of dengue fever cases is driving the growth of the dengue vaccine market.

Market Trends –

Major companies operating in the dengue vaccine market are focused on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, to enhance protection against all four dengue virus serotypes in a single formulation. The dengue tetravalent vaccine provides immunity against all four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, received European Commission (EC) approval for QDENGA vaccine use in individuals from 4 years of age and older. It is a live-attenuated vaccine used in several dengue-endemic countries to protect against dengue fever. It uses a weakened dengue serotype two viruses as a genetic foundation for the other three serotypes. It is administered in two doses of 0.5 mL each at 0 and 3 months and targets individuals aged four years and older. A Phase 3 trial showed Qdenga has an efficacy of about 80.2% against dengue, with better results in preventing hospitalizations. Its protection lasts approximately 4.5 years, longer than many other vaccines.

The dengue vaccine market covered in this report is segmented –

1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine

2) By Vaccine Phase: Phase I, Phase II, Phase III

3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users

Get an inside scoop of the dengue vaccine market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

Regional Insights –

Asia-Pacific was the largest region in the dengue vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Table of Contents